Does the underlying haemodynamic abnormality determine response to antihypertensive therapy in patients with hypertension? - Does the underlying haemodynamic abnormality determine response to antihypertensive therapy?

Cambridge University Hospitals NHS Foundation Trust jointly with University of Cambridge0 个研究点目标入组 60 人开始时间: 2007年4月26日最近更新: 2019年6月30日

适应症

试验速览

暂无简介。

•Hypertension will be defined as seated pressure >140/90mmHg confirmed on 3 occasions.
•To be included in the study the patient must have/be:
•Male or female
•Aged 18-80 years
•Able to give informed consent
•Newly diagnosed treatment naïve hypertensives or
•On at least two antihypertensive agents consisting of and ‘A’ drug (angiotension-2-receptor blocker or ACE-inhibitor) and a diuretic and not reaching target blood pressure and willing to change medication as below.
•If patients are on more than 2 antihypertensive agents and not at target they will be switched to a combination of ACE-inhibitor, diuretic and calcium channel blocker according to current British Hypertension Society guidelines. If they remain above target they will be enrolled in the study. If switching their medication makes their blood pressure consistently worse by >20/10 mmHg they will not be enrolled in the study.
•Female patients of child bearing age will have a pregnancy test.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Subjects with secondary hypertension, uncontrolled hypertension (>200/110), pregnant or nursing women and women of childbearing age not taking contraceptives or refusing a pregnancy test will be excluded.
•Patients with contraindications to the study or necessary background medication such as gout, asthma as well as subjects with intolerances to any of the study medication will not be enrolled in the study. Possible interactions of the study medication with the patients’ concomitant medication will be considered and the patient excluded from the study if appropriate.
•Subjects with heart failure NYHA stage 3 or 4, liver failure (defined as an elevation of ALT four times above upper limit of normal) , renal failure (chronic kidney disease stage 3 or 4) and terminal illnesses (e.g. cancer) as well as very frail patients will be excluded.
•Patients whose blood pressure consistently rises by more than 20/10mmHg by switching their medication following their screening visit will not be enrolled in the study.
•Patients unable to give informed consent will not be enrolled.

发起方

Cambridge University Hospitals NHS Foundation Trust jointly with University of Cambridge